Vertex Pharmaceuticals Down Over 18%, on Pace for Largest Percent Decrease Since November 2003 -- Data Talk

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $221.93, down $49.53 or 18.25%

-- Would be lowest close since March 27, 2020, when it closed at $217.24

-- On pace for largest percent decrease since Nov. 11, 2003, when it fell 36.76%

-- Earlier Thursday, SVB Leerink cut its price target on Vertex Pharmaceuticals to $267.00/share from $283.00/share, Benzinga reported

-- After the close of trading on Wednesday, Vertex announced it would discontinue its Phase 2 study of protein-deficiency drug VX-814 in patients with alpha-1 antitrypsin deficiency and stop development because of safety concerns. Alpha-1 antitrypsin deficiency is a genetic disorder that can cause lung or liver disease

-- Currently down two consecutive days; down 19.62% over this period

-- Worst two day stretch since the two days ending Nov. 5, 2007, when it fell 23.89%

-- Down 18.44% month-to-date

-- Up 1.36% year-to-date

-- Down 26.78% from its all-time closing high of $303.10 on July 20, 2020

-- Up 24.88% from 52 weeks ago (Oct. 17, 2019), when it closed at $177.72

-- Down 26.78% from its 52-week closing high of $303.10 on July 20, 2020

-- Up 25.93% from its 52-week closing low of $176.23 on Oct. 18, 2019

-- Traded as low as $221.25; lowest intraday level since March 30, 2020, when it hit $220.00

-- Down 18.5% at today's intraday low; largest intraday percent decrease since June 28, 2012, when it fell as much as 21.68%

-- Worst performer in the S&P 500 today

-- Worst performer in the Nasdaq 100 today